Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study

scientific article published on 10 December 2016

Efficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/1346-8138.13713
P698PubMed publication ID27943425

P50authorErkan AlpsoyQ57023526
Andac SalmanQ87793125
Abdullah SariozQ89766763
P2093author name stringNahide Onsun
Tulin Ergun
Dilek Seckin Gencosmanoglu
Emel Bulbul-Baskan
Merve Hatun Saricam
P2860cites workInterventions to enhance patient adherence to medication prescriptions: scientific review.Q30873367
Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review.Q33841408
How children's responses to drugs differ from adultsQ35827035
Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literatureQ36030689
Factors and Mechanisms for Pharmacokinetic Differences between Pediatric Population and AdultsQ37378093
Systemic treatments for severe pediatric psoriasis: a practical approachQ38096108
Systemic treatments in paediatric psoriasis: a systematic evidence-based update.Q38262843
Methotrexate in pediatric plaque-type psoriasis: Long-term daily clinical practice results from the Child-CAPTURE registryQ41610932
Evidence for pre-hepatic metabolism of oral cyclosporine in childrenQ42081648
Systemic methotrexate treatment in childhood psoriasis: further experience in 24 children from IndiaQ42170488
Treatment of childhood psoriasis with phototherapy and photochemotherapyQ42541599
Epidemiology and comorbidity of psoriasis in childrenQ44208093
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.Q44769660
Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS studyQ46649650
Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging studyQ46719856
Health-related quality of life of pediatric patients with moderate to severe plaque psoriasis: comparisons to four common chronic diseasesQ48580332
P433issue6
P921main subjectmulticenter clinical trialQ6934595
P304page(s)630-634
P577publication date2016-12-10
P1433published inThe Journal of DermatologyQ18225322
P1476titleEfficacy, safety and drug survival of conventional agents in pediatric psoriasis: A multicenter, cohort study
P478volume44